Atai Life Sciences
Prix: 3.92Entreprise et modèle économique
Atai Life Sciences is a biotechnology company focused on developing innovative treatments for mental health disorders. Its core products include psychedelic compounds and therapies aimed at addressing conditions such as depression and anxiety. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations, licensing agreements, and potential future product sales.
Profil d’investissement
The investment profile of Atai Life Sciences is more aligned with growth investors, given its focus on developing novel therapies and the potential for significant market impact. However, the company's current financial performance indicates higher risk, making it less suitable for conservative investors seeking stable returns. The stock may appeal to those with a medium to long-term investment horizon, as it navigates the complexities of drug development and regulatory approval.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -3.00 Risque
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -10.5% ↓
- Surprise BPA
- 27.3% meilleur que prévu
- Volatilité 20 j
- 4.3% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-05 02:55 | Conserver | Vendre | Weak fundamentals and high risk limit upside potential. |
| 2026-05-28 02:35 | Vendre | Conserver | Weak fundamentals and high risk limit upside potential. |
| 2026-05-20 02:35 | Conserver | Vendre | scenario_deterioration |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-04-20 11:57 | Canaccord Genuity | Objectif relevé | 14 → 15 | 5.2 |
| 2026-03-27 08:52 | Deutsche Bank | Mettre à jour | — → 12 | 3.35 |
| 2026-03-06 20:37 | Jefferies | Mettre à jour | — → 10 | 3.39 |
Rien pour le moment